-Bloomberg
Why This Citius Analyst Thinks The Biopharma’s Shares Present 375% Upside Potential
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced earlier this week an agreement with Dr.
Related Posts
Top Financial Stories Tuesday, September 6: Focus on iPhone 14 Event, OPEC+ Plans Mild Production Cut, Netflix Says No To Crypto Ads And More…
Reuters
EQT Corp Close To Buying THQ Appalachia
If You Invested $1,000 In Walt Disney’s Stock One Year Ago, Here’s How Much You’d Have Now
Investors who have owned stocks in the past year have generally experienced some decent gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return over the past 12 months is 17.2%. But there is no question some big-name stocks performed better than others along the way.
